veledimex
Gene therapyexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00815607)
Timeline
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C- Mol. weight
- 438.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039523 ↗
Also known as
- inxn-1001
- inxn-1001
- inxn-1001
- veledimex
- veledimex
- veledimex
- veledimex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04006119 | Phase 2 | Jun 28, 2019 | Ziopharm |
| NCT03740724 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2019 | Fibrocell Technologies, Inc. |
| NCT03679754 | Phase 1 | Sep 30, 2018 | Ziopharm |
| NCT03636477 | Phase 1 | Jun 18, 2018 | Ziopharm |
| NCT03330197 | Phase 1 | Sep 26, 2017 | Ziopharm |
| NCT02026271 | Phase 1 | Jun 1, 2015 | Ziopharm |
| NCT02423902 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Ziopharm |
| NCT01703754 | Phase 2 | Mar 1, 2013 | Ziopharm |
| NCT01397708 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Ziopharm |
| NCT00815607 | Phase 1 | Apr 1, 2009 | Ziopharm |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ziopharm | For profit | 9 | 9 | 2 | 2009 |
| Fibrocell Technologies, Inc. | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1